News

Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials
Q1 2025 Management View CEO Mark Goldsmith highlighted significant advancements in the company's strategic priorities, particularly in the development of RAS(ON) inhibitors targeting RAS-addicted ...
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs
Baystreet.ca News Commentary – Innovation in biotech is rapidly reshaping how we fight cancer, a trend reflected in the ...